Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28248925 | 0.89 | CYP2A6 (0.44) | ALDH1A1CYP2A6ARCYP11B1CYP11B2 | |
| SCHEMBL10304853 | 0.85 | KIF11 (0.43) | ALDH1A1CYP2A6HPGD | |
| SCHEMBL10304761 | 0.83 | CYP2A6 (0.43) | ALDH1A1CYP2A6ARLMNACYP11B1 | |
| SCHEMBL13377029 | 0.83 | CYP2A6 (0.41) | ALDH1A1CYP2A6TRPA1LMNACHRM1 | |
| SCHEMBL19464642 | 0.81 | CYP2A6 (0.38) | ALDH1A1CYP2A6ARGLA | |
| SCHEMBL23603542 | 0.81 | PGR (0.44) | ALDH1A1AR | |
| SCHEMBL16954750 | 0.79 | ALDH1A1 (0.41) | ALDH1A1HPGDTRPA1LMNACHRM1 | |
| SCHEMBL19425844 | 0.79 | PTGDR2 (0.42) | ALDH1A1CYP2A6ARTRPA1LMNA | |
| SCHEMBL19987487 | 0.79 | CRHR1 (0.42) | ALDH1A1CYP2A6AR | |
| SCHEMBL21336611 | 0.78 | CYP2A6 (0.36) | ALDH1A1CYP2A6ARGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006559-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-16 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-09 | — | — | US | disclosed |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-06-18 | — | — | US | disclosed |
| EP-2060579-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-05-20 | — | — | EP | disclosed |
| EP-2055710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | ALDH1A1 111/4885CYP2A6 10/4885HPGD 185/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | ALDH1A1 58/4885CYP2A6 158/4885HPGD 3921/4885 |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | ALPI, IK, ALDH1A2 | ALDH1A1 59/4885CYP2A6 3866/4885HPGD 3590/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | ALDH1A1 2971/4885CYP2A6 3790/4885HPGD 1990/4885 |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | ALDH1A1 5/4885CYP2A6 3248/4885HPGD 3081/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | ALDH1A1 2035/4885CYP2A6 2953/4885HPGD 1511/4885 |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | ALDH1A1 989/4885CYP2A6 2450/4885HPGD 39/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885CYP2A6 2442/4885HPGD 1521/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885CYP2A6 2442/4885HPGD 1521/4885 |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | ALDH1A1 5/4885CYP2A6 3248/4885HPGD 3081/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | ALDH1A1 3702/4885CYP2A6 4460/4885HPGD 2408/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | ALDH1A1 2149/4885CYP2A6 3831/4885HPGD 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.